Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation
Jieli Wei, Fanye Meng, Kwang‐Su Park, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 37, pp. 15073-15083
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1856
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 172
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 170
Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation
Yu Chen, Ira Tandon, William J. Heelan, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 13, pp. 5330-5350
Open Access | Times Cited: 141
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 92
Expanding PROTACtable genome universe of E3 ligases
Yuan Liu, Jingwen Yang, Tianlu Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 72
Discovery of E3 Ligase Ligands for Target Protein Degradation
Jaeseok Lee, Young‐Jun Lee, Young Mee Jung, et al.
Molecules (2022) Vol. 27, Iss. 19, pp. 6515-6515
Open Access | Times Cited: 70
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
Yan Xiong, Yue Zhong, Hyerin Yim, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 49, pp. 22622-22632
Open Access | Times Cited: 70
Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation
Shaowen Xie, Feiyan Zhan, Jingjie Zhu, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 13
Open Access | Times Cited: 47
Piperlongumine conjugates induce targeted protein degradation
Jing Pei, Yufeng Xiao, Xingui Liu, et al.
Cell chemical biology (2023) Vol. 30, Iss. 2, pp. 203-213.e17
Open Access | Times Cited: 43
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Martin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 39
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Yilin Chen, Haoan Xue, Jianping Jin
Journal of Biological Chemistry (2024) Vol. 300, Iss. 5, pp. 107264-107264
Open Access | Times Cited: 17
Smart Nano‐PROTACs Reprogram Tumor Microenvironment for Activatable Photo‐metabolic Cancer Immunotherapy
Chi Zhang, Shasha He, Ziling Zeng, et al.
Angewandte Chemie International Edition (2021) Vol. 61, Iss. 8
Closed Access | Times Cited: 100
Predicting the structural basis of targeted protein degradation by integrating molecular dynamics simulations with structural mass spectrometry
Tom Dixon, Derek MacPherson, Barmak Mostofian, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 66
Exploring the target scope of KEAP1 E3 ligase-based PROTACs
Guangyan Du, Jie Jiang, Nathaniel J. Henning, et al.
Cell chemical biology (2022) Vol. 29, Iss. 10, pp. 1470-1481.e31
Open Access | Times Cited: 53
Expanding the landscape of E3 ligases for targeted protein degradation
Luke T. Kramer, Xiaoyu Zhang
Current Research in Chemical Biology (2022) Vol. 2, pp. 100020-100020
Open Access | Times Cited: 47
Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
Xin Han, Yi Sun
Cell Reports Physical Science (2022) Vol. 3, Iss. 10, pp. 101062-101062
Open Access | Times Cited: 46
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Hui Ming, Bowen Li, Jingwen Jiang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 30
Bromodomain inhibitors and therapeutic applications
G. Bharath Kumar, Ming‐Ming Zhou
Current Opinion in Chemical Biology (2023) Vol. 75, pp. 102323-102323
Open Access | Times Cited: 30
Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53
Md Kabir, Ning Sun, Xiao Hu, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 27, pp. 14932-14944
Closed Access | Times Cited: 28
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
E3 ligase ligand optimization of Clinical PROTACs
Hanrui Jiang, Huan Xiong, Shuang-Xi Gu, et al.
Frontiers in Chemistry (2023) Vol. 11
Open Access | Times Cited: 26
E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology
Iacovos N. Michaelides, Gavin W. Collie
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3173-3194
Open Access | Times Cited: 26
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top